Insights Into the Role of Infection in Atherogenesis and in Plaque Rupture

被引:118
作者
Epstein, Stephen E. [1 ]
Zhu, Jianhui [1 ]
Najafi, Amir H. [1 ]
Burnett, Mary S. [1 ]
机构
[1] Washington Hosp Ctr, Inst Cardiovasc Res, MedStar Res Inst, Washington, DC 20010 USA
关键词
atherosclerosis; infection; inflammation; CORONARY-ARTERY-DISEASE; SMOOTH-MUSCLE-CELLS; CHLAMYDIA-PNEUMONIAE INFECTION; HERPES-SIMPLEX-VIRUS; ACUTE MYOCARDIAL-INFARCTION; HEAT-SHOCK PROTEINS; HELICOBACTER-PYLORI INFECTION; RANDOMIZED CONTROLLED-TRIALS; LOW-DENSITY-LIPOPROTEIN; LONG-TERM PROGNOSIS;
D O I
10.1161/CIRCULATIONAHA.109.849455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In summary, compelling data indicate that infection does contribute to atherogenesis and to the acute complications of atherosclerosis caused by plaque rupture. What has clearly emerged over the past decade, however, is that there are profound complexities inherent in the interactions that occur between different pathogens and a variety of genetically determined host factors, each of which profoundly alters the host's response to infection (Figure 2); these include the host's susceptibility to infection, the magnitude of the host's inflammatory response to a given infection, and whether the host is predisposed to develop an autoimmune response. Therefore, whether a specific pathogen (or combination of pathogens) will initiate, cause progression of, or precipitate one of the acute complications of atherosclerosis will be determined by these complex factors and their complex interactions. It would thus appear that we need considerably more information about an individual's genetically based susceptibility to infection, to inflammation, and to immune responses before we can adequately predict how pathogens influence atherogenesis and its complications in the individual patient. © 2009 American Heart Association, Inc.
引用
收藏
页码:3133 / U160
页数:13
相关论文
共 104 条
[11]   Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Grayston, JT ;
Muhlestein, B ;
Giugliano, RP ;
Cairns, R ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (16) :1646-1654
[12]   Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial [J].
Cercek, B ;
Shah, PK ;
Noc, M ;
Zahger, D ;
Zeymer, U ;
Matetzky, S ;
Maurer, G ;
Mahrer, P .
LANCET, 2003, 361 (9360) :809-813
[13]  
Chiu B, 1997, CIRCULATION, V96, P2144
[14]   HEAT-SHOCK PROTEINS EXPRESSED ON THE SURFACE OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE I-INFECTED CELL-LINES INDUCE AUTOANTIBODIES IN RABBITS [J].
CHOUCHANE, L ;
BOWERS, FS ;
SAWASDIKOSOL, S ;
SIMPSON, RM ;
KINDT, TJ .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02) :253-259
[15]   Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s) [J].
Coombes, BK ;
Mahony, JB .
INFECTION AND IMMUNITY, 1999, 67 (06) :2909-2915
[16]   Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression -: A potential link to accelerated arteriosclerosis [J].
Dechend, R ;
Maass, M ;
Gieffers, J ;
Dietz, R ;
Scheidereit, C ;
Leutz, A ;
Gulba, DC .
CIRCULATION, 1999, 100 (13) :1369-1373
[17]   Expression of toll-like receptors in human atherosclerotic lesions - A possible pathway for plaque activation [J].
Edfeldt, K ;
Swedenborg, J ;
Hansson, GK ;
Yan, ZQ .
CIRCULATION, 2002, 105 (10) :1158-1161
[18]   Lack of association of infectious agents with risk of future myocardial infarction and stroke - Definitive evidence disproving the infection/coronary artery disease hypothesis? [J].
Epstein, SE ;
Zhu, JH .
CIRCULATION, 1999, 100 (13) :1366-1368
[19]   Infection and atherosclerosis - Emerging mechanistic paradigms [J].
Epstein, SE ;
Zhou, YF ;
Zhu, JH .
CIRCULATION, 1999, 100 (04) :E20-E28
[20]   Janus phenomenon - The interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis [J].
Epstein, SE ;
Stabile, E ;
Kinnaird, T ;
Lee, CW ;
Clavijo, L ;
Burnett, MS .
CIRCULATION, 2004, 109 (23) :2826-2831